collection
MENU ▼
Read by QxMD icon Read
search

cardiotoxicity

shared collection
65 papers 0 to 25 followers
By Elvis Amao Internal Medicine , Cardiology and infectious diseases
https://www.readbyqxmd.com/read/27911951/body-surface-area-and-baseline-blood-pressure-predict-subclinical-anthracycline-cardiotoxicity-in-women-treated-for-early-breast-cancer
#1
Paul Kotwinski, Gillian Smith, Jackie Cooper, Julie Sanders, Louise Ma, Albert Teis, David Kotwinski, Michael Mythen, Dudley J Pennell, Alison Jones, Hugh Montgomery
BACKGROUND AND AIMS: Anthracyclines are highly effective chemotherapeutic agents which may cause long-term cardiac damage (chronic anthracycline cardiotoxicity) and heart failure. The pathogenesis of anthracycline cardiotoxicity remains incompletely understood and individual susceptibility difficult to predict. We sought clinical features which might contribute to improved risk assessment. METHODS: Subjects were women with early breast cancer, free of pre-existing cardiac disease...
2016: PloS One
https://www.readbyqxmd.com/read/27903214/chemotherapy-and-cardiotoxicity-in-hematologic-malignancies-a-review
#2
Antonio Stellitano, Roberta Fedele, Santina Barillà, Antonino Iaria, Carmelo Massimiliano Rao, Massimo Martino
Antineoplastic agents affect the cardiovascular system, and the incidence of cardiotoxicity is continuously growing in patients with hematologic malignancies and treated with antineoplastic therapy. Cardio-oncology is a quite young discipline, designed for diagnosis, prevention and treatment of cardiovascular complications of anticancer agents. Nowadays, with the current treatments and an accurate pharmacological control of comorbidities present at the time of the oncological diagnosis, early clinical events are infrequent, and it seems indeed that cardiotoxicity could emerge as time and years go by, after therapies completion...
November 21, 2016: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/27878803/tissue-doppler-echocardiography-detects-subclinical-left-ventricular-dysfunction-in-patients-undergoing-chemotherapy-for-colon-cancer-insights-from-oncoecho-multicenter-study
#3
Edyta Płońska-Gościniak, Monika Różewicz, Jarosław Kasprzak, Andrzej Wojtarowicz, Katarzyna Mizia-Stec, Tomasz Hryniewiecki, Piotr Pysz, Andrzej Kułach, Artur Bodys, Violetta Sulżyc, Wojciech Braksator, Andrzej Szyszka, Beata Zaborska, Adrianna Gościńska-Szmagała, Maciej Siński, Dariusz Kosior, Ilona Kowalik, Zbigniew Gąsior
I BACKGROUND: Colorectal cancer (CRC) is the second most common cancer in women and the third in men in Poland. The role of chemotherapy (CTX) depends on stage of CRC: adjuvant CTX is a standard treatment in stage III and should also be considered in stage II with risk factors. AIM: The aim of the paper was to assess the cardiovascular consequences of CTX in CRC enrolled to the ONCOECHO multicenter study (2012 - 2014). To identify potential cardiotoxicity we focused on myocardial function, heart rhythm and conduction disorders and adverse cardiovascular events...
November 23, 2016: Kardiologia Polska
https://www.readbyqxmd.com/read/27842711/-radiation-related-heart-toxicity-update-in-women
#4
S Marlière, E Vautrin, C Saunier, A Chaikh, I Gabelle-Flandin
Breast cancer is a common diagnosis in women and thus women are at risk of radiation-induced heart disease, in particular during radiotherapy for left breast cancer and when the internal mammary chain is included. Rates of major cardiac events increase with younger age at the time of irradiation, diagnosis before 1990s, higher radiation doses, coexisting cardiovascular risk factors and adjuvant cardiotoxic chemotherapy. Radiation-induced heart disease comprises a spectrum of cardiac pathologies, including pericardial disease, cardiomyopathy, coronary artery disease and valvular disease...
December 2016: Annales de Cardiologie et D'angéiologie
https://www.readbyqxmd.com/read/27829985/potential-therapeutic-strategies-for-hypertension-exacerbated-cardiotoxicity-of-anticancer-drugs
#5
REVIEW
Robin K Kuriakose, Rakesh C Kukreja, Lei Xi
Despite their recognized cardiotoxic effects, anthracyclines remain an essential component in many anticancer regimens due to their superior antitumor efficacy. Epidemiologic data revealed that about one-third of cancer patients have hypertension, which is the most common comorbidity in cancer registries. The purpose of this review is to assess whether anthracycline chemotherapy exacerbates cardiotoxicity in patients with hypertension. A link between hypertension comorbidity and anthracycline-induced cardiotoxicity (AIC) was first suggested in 1979...
2016: Oxidative Medicine and Cellular Longevity
https://www.readbyqxmd.com/read/27830273/-summary-of-the-esc-position-paper-on-cancer-treatment-and-cardiovascular-toxicity
#6
J Hoog, S Achenbach
The numbers of survivors of cancer have increased as a consequence of advances in chemotherapy; however, the side effects of cancer treatment have become increasingly more important. The most frequent side effects include cardiovascular complications, which can lead to acute and delayed morbidity and mortality, often many years later. The discipline of cardio-oncology deals with the prevention, diagnostics and treatment of cardiovascular diseases caused by cancer therapy. The most important cardiovascular side effects of cytostatic therapy are heart failure due to myocardial dysfunction (cardiotoxicity), coronary artery disease, valvular disease and ventricular arrhythmia as a result of QT extension...
December 2016: Herz
https://www.readbyqxmd.com/read/27816693/are-cardioprotective-effects-of-no-releasing-drug-molsidomine-translatable-to-chronic-anthracycline-cardiotoxicity-settings
#7
Olga Lenčová-Popelová, Hana Jansová, Eduard Jirkovský, Jan Bureš, Anna Jirkovská-Vávrová, Yvona Mazurová, Petra Reimerová, Lucie Vostatková, Michaela Adamcová, Miloš Hroch, Zuzana Pokorná, Petra Kovaříková, Tomáš Šimůnek, Martin Štěrba
Chronic anthracycline (ANT) cardiotoxicity is a serious complication of cancer chemotherapy. Molsidomine, a NO-releasing drug, has been found cardioprotective in different models of I/R injury and recently in acute high-dose ANT cardiotoxicity. Hence, we examined whether its cardioprotective effects are translatable to chronic ANT cardiotoxicity settings without induction of nitrosative stress and interference with antiproliferative action of ANTs. The effects of molsidomine (0.025 and 0.5mg/kg, i.v.) were studied on the well-established model of chronic ANT cardiotoxicity in rabbits (daunorubicin/DAU/3mg/kg/week for 10 weeks)...
November 30, 2016: Toxicology
https://www.readbyqxmd.com/read/27799559/vegf-b-gene-therapy-inhibits-doxorubicin-induced-cardiotoxicity-by-endothelial-protection
#8
Markus Räsänen, Joni Degerman, Tuuli A Nissinen, Ilkka Miinalainen, Risto Kerkelä, Antti Siltanen, Janne T Backman, Eero Mervaala, Juha J Hulmi, Riikka Kivelä, Kari Alitalo
Congestive heart failure is one of the leading causes of disability in long-term survivors of cancer. The anthracycline antibiotic doxorubicin (DOX) is used to treat a variety of cancers, but its utility is limited by its cumulative cardiotoxicity. As advances in cancer treatment have decreased cancer mortality, DOX-induced cardiomyopathy has become an increasing problem. However, the current means to alleviate the cardiotoxicity of DOX are limited. We considered that vascular endothelial growth factor-B (VEGF-B), which promotes coronary arteriogenesis, physiological cardiac hypertrophy, and ischemia resistance, could be an interesting candidate for prevention of DOX-induced cardiotoxicity and congestive heart failure...
November 15, 2016: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/27800661/incidence-time-of-occurrence-and-response-to-heart-failure-therapy-in-patients-with-anthracycline-cardiotoxicity
#9
Arshad A Khan, Asma Ashraf, Rajinder Singh, Adil Rahim, Walid Rostom, Mumtaz Hussain, Ian Renner, Nicholas J Collins
BACKGROUND: Anthracyclines are commonly used chemotherapeutic medications. In the current analysis we evaluated all-cause mortality and incidence, timing and response to medical therapy of anthracycline cardiotoxicity. METHODS: Left ventricular ejection fraction (LVEF) was serially assessed using gated heart pool scan/echocardiography in patients receiving anthracycline based chemotherapy from January 2009 to December 2014. RESULTS: A total of 1204 patients were administered anthracyclines during the study period...
November 1, 2016: Internal Medicine Journal
https://www.readbyqxmd.com/read/27717837/an-integrative-view-of-cisplatin-induced-renal-and-cardiac-toxicities-molecular-mechanisms-current-treatment-challenges-and-potential-protective-measures
#10
REVIEW
George J Dugbartey, Luke J Peppone, Inge A M de Graaf
Cisplatin is currently one of the most widely-used chemotherapeutic agents against various malignancies. Its clinical application is limited, however, by inherent renal and cardiac toxicities and other side effects, of which the underlying mechanisms are only partly understood. Experimental studies show cisplatin generates reactive oxygen species, which impair the cell's antioxidant defense system, causing oxidative stress and potentiating injury, thereby culminating in kidney and heart failure. Understanding the molecular mechanisms of cisplatin-induced renal and cardiac toxicities may allow clinicians to prevent or treat this problem better and may also provide a model for investigating drug-induced organ toxicity in general...
September 14, 2016: Toxicology
https://www.readbyqxmd.com/read/27713603/the-early-predictive-value-of-right-ventricular-strain-in-epirubicin-induced-cardiotoxicity-in-patients-with-breast-cancer
#11
Wei-Ting Chang, Jhih-Yuan Shih, Yin-Hsun Feng, Chun-Yen Chiang, Yu Hsuan Kuo, Wei-Yu Chen, Hong-Chang Wu, Juei-Tang Cheng, Jhi-Joung Wang, Zhih-Cherng Chen
BACKGROUND: As cancer therapies have improved, patient life spans have been extended but quality of life has been threatened by chemotherapy induced cardiotoxicity. Most cardiac complications remain unobserved until specific symptoms develop. Speckle-tracking echocardiography is a sensitive imaging modality in detecting early occult myocardial dysfunction. METHODS: A total number of 35 patients newly diagnosed with breast cancer and preparing for epirubicin therapy were prospectively recruited...
September 2016: Acta Cardiol Sin
https://www.readbyqxmd.com/read/27660573/cardio-oncology-a-focused-review-of-anthracycline-human-epidermal-growth-factor-receptor-2-inhibitor-and-radiation-induced-cardiotoxicity-and-management
#12
REVIEW
Jean Domercant, Nichole Polin, Eiman Jahangir
BACKGROUND: Cardio-oncology is a collaborative approach between cardiologists and oncologists in the treatment of patients with cancer and heart disease. Radiation and chemotherapy have played a major role in the decreased cancer-related mortality achieved in the past 2 decades. However, anthracycline-, tyrosine kinase-, and radiation-based therapies are each associated with independent cardiovascular (CV) risks, and these risks are cumulative when these therapies are used in combination...
2016: Ochsner Journal
https://www.readbyqxmd.com/read/27629548/rationale-and-design-of-the-multidisciplinary-team-intervention-in-cardio-oncology-study-titan
#13
Edith Pituskin, Mark Haykowsky, Margaret McNeely, John Mackey, Neil Chua, Ian Paterson
BACKGROUND: Cancer is the leading cause of premature death in Canada. In the last decade, important gains in cancer survival have been achieved by advances in adjuvant treatment. However, many oncologic treatments also result in cardiovascular "toxicity". Furthermore, cardiac risk factors such as hypertension, dyslipidemia, and diabetes mellitus are known to contribute to the progression of cardiac damage and clinical cardiotoxicity. As such, for many survivors, the risk of death from cardiac disease exceeds that of recurrent cancer...
September 15, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27609196/validating-the-pharmacogenomics-of-chemotherapy-induced-cardiotoxicity-what-is-missing
#14
REVIEW
Tarek Magdy, Brian T Burmeister, Paul W Burridge
The cardiotoxicity of certain chemotherapeutic agents is now well-established, and has led to the development of the field of cardio-oncology, increased cardiac screening of cancer patients, and limitation of patients' maximum cumulative chemotherapeutic dose. The effect of chemotherapeutic regimes on the heart largely involves cardiomyocyte death, leading to cardiomyopathy and heart failure, or the induction of arrhythmias. Of these cardiotoxic drugs, those resulting in clinical cardiotoxicity can range from 8 to 26% for doxorubicin, 7-28% for trastuzumab, or 5-30% for paclitaxel...
December 2016: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27566332/echocardiographic-assessment-of-cardiotoxic-effects-of-cancer-therapy
#15
REVIEW
Wendy J Bottinor, Christopher K Migliore, Carrie A Lenneman, Marcus F Stoddard
Patients with cancer can present with difficult management issues, as the medicine can sometimes cause sequelae destructive to healthy tissue. As this population lives longer, cardiotoxic effects are beginning to emerge, but the early recognition of this signal can prove difficult, with too late a recognition leading to lifelong cardiac impairment and dysfunction. Cardio-oncology can bridge this difficulty, and echocardiography and its newer imaging abilities are proving efficacious in this population. This article will address common sequelae of cardiotoxic treatment regimens and offer recommendations for echocardiographic surveillance...
October 2016: Current Cardiology Reports
https://www.readbyqxmd.com/read/27552363/medical-interventions-for-treating-anthracycline-induced-symptomatic-and-asymptomatic-cardiotoxicity-during-and-after-treatment-for-childhood-cancer
#16
REVIEW
Daniel K L Cheuk, Elske Sieswerda, Elvira C van Dalen, Aleida Postma, Leontien C M Kremer
BACKGROUND: Anthracyclines are frequently used chemotherapeutic agents for childhood cancer that can cause cardiotoxicity during and after treatment. Although several medical interventions in adults with symptomatic or asymptomatic cardiac dysfunction due to other causes are beneficial, it is not known if the same treatments are effective for childhood cancer patients and survivors with anthracycline-induced cardiotoxicity. This review is an update of a previously published Cochrane review...
2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27508008/research-progress-of-cardioprotective-agents-for-prevention-of-anthracycline-cardiotoxicity
#17
REVIEW
Jing Zhang, Xiaohai Cui, Yan Yan, Min Li, Ya Yang, Jiansheng Wang, Jia Zhang
Anthracyclines, including doxorubicin, epirubicin, daunorubicin and aclarubicin, are widely used as chemotherapeutic agents in the treatment of hematologic and solid tumor, including acute leukemia, lymphoma, breast cancer, gastric cancer, soft tissue sarcomas and ovarian cancer. In the cancer treatment, anthracyclines also can be combined with other chemotherapies and molecular-targeted drugs. The combination of anthracyclines with other therapies is usually the first-line treatment. Anthracyclines are effective and potent agents with a broad antitumor spectrum, but may cause adverse reactions, including hair loss, myelotoxicity, as well as cardiotoxicity...
2016: American Journal of Translational Research
https://www.readbyqxmd.com/read/27503589/organization-and-implementation-of-a-cardio-oncology-program
#18
Manuela Fiuza, Leonor Ribeiro, Andreia Magalhães, Ana Rita Sousa, Miguel Nobre Menezes, Marília Jorge, Luís Costa, Fausto José Pinto
Considerable advances in cancer therapies in recent decades have reshaped the prognosis of cancer patients. There are now estimated to be over 20 million cancer survivors in the USA and Europe, numbers unimaginable a few years ago. However, this increase in survival, along with the aging of the patient population, has been accompanied by a rise in adverse cardiovascular effects, particularly when there is a previous history of heart disease. The incidence of cardiotoxicity continues to grow, which can compromise the effectiveness of cancer therapy...
September 2016: Portuguese Journal of Cardiology: An Official Journal of the Portuguese Society of Cardiology
https://www.readbyqxmd.com/read/27502031/heart-failure-following-cancer-treatment-characteristics-survival-and-mortality-of-a-linked-health-data-analysis
#19
Robyn A Clark, Narelle M Berry, Munir H Chowdhury, Alexandra L McCarthy, Shahid Ullah, Vincent L Versace, John J Atherton, Bogda Koczwara, David Roder
BACKGROUND: Cardiotoxicity resulting in heart failure is a devastating complication of cancer therapy. A patient may survive cancer only to develop heart failure (HF) which has a higher mortality rate than some cancers. AIM: This project aimed to describe the characteristics and outcomes of HF in patients with blood or breast cancer after chemotherapy treatment. METHODS: Queensland Cancer Registry, Death Registry and Hospital Administration records were linked (1996-2009)...
August 9, 2016: Internal Medicine Journal
https://www.readbyqxmd.com/read/27490685/biomarkers-for-presymptomatic-doxorubicin-induced-cardiotoxicity-in-breast-cancer-patients
#20
Valentina K Todorova, Issam Makhoul, Eric R Siegel, Jeanne Wei, Annjanette Stone, Weleetka Carter, Marjorie L Beggs, Aaron Owen, V Suzanne Klimberg
Cardiotoxicity of doxorubicin (DOX) remains an important health concern. DOX cardiotoxicity is cumulative-dose-dependent and begins with the first dose of chemotherapy. No biomarker for presymptomatic detection of DOX cardiotoxicity has been validated. Our hypothesis is that peripheral blood cells (PBC) gene expression induced by the early doses of DOX-based chemotherapy could identify potential biomarkers for presymptomatic cardiotoxicity in cancer patients. PBC gene expression of 33 breast cancer patients was conducted before and after the first cycle of DOX-based chemotherapy...
2016: PloS One
label_collection
label_collection
6870
1
2
2016-08-07 11:19:48
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"